SCHEMBL25172068

SCHEMBL25172068

CC(C)(C)OC(=O)N1CCN(c2cnc(Cc3ccccc3)nc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 5/20 0.56
▸ ACHE P22303 1/20 0.54
▸ CKS1B P61024 2/20 0.54
▸ SKP1 P63208 2/20 0.54
▸ SKP2 Q13309 2/20 0.54
▸ ALK Q9UM73 1/20 0.51
▸ PIK3CA P42336 1/20 0.49
▸ MAPT P10636 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ PTPN11 Q06124 1/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NAMPT P43490 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ RORC P51449 1/20 0.46
▸ KIT P10721 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881674 0.84 GPR119 (0.61) GPR119ACHECKS1BSKP1SKP2
SCHEMBL713180 0.82 GPR119 (0.61) GPR119ACHECKS1BSKP1SKP2
SCHEMBL3331628 0.81 GPR119 (0.76) GPR119ACHECKS1BSKP1SKP2
SCHEMBL25177953 0.81 GPR119 (0.58) GPR119ACHECKS1BSKP1SKP2
SCHEMBL30373812 0.81 GPR119 (0.58) GPR119ACHECKS1BSKP1SKP2
SCHEMBL25178650 0.80 ACHE (0.53) GPR119ACHECKS1BSKP1SKP2
SCHEMBL1458887 0.79 GPR119 (0.76) GPR119CKS1BSKP1SKP2MAPT
SCHEMBL20311204 0.79 GPR119 (0.57) GPR119CKS1BSKP1SKP2PIK3CA
SCHEMBL31111540 0.79 GPR119 (0.57) GPR119CKS1BSKP1SKP2PIK3CA
SCHEMBL6263583 0.78 GPR119 (0.61) GPR119ACHECKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 — — US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 — — EP disclosed
CN-118475580-A Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof 普罗根托斯治疗公司 2024-08-09 — — CN disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA GPR119 842/4885ACHE 4222/4885CKS1B 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback